Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,260.00 JPY | -0.03% | -0.58% | -6.05% |
Dec. 29 | Mitsui Chemicals Spends 2.16 Billion Yen in Share Repurchase | MT |
Dec. 24 | Tranche Update on Mitsui Chemicals, Inc.'s Equity Buyback Plan announced on November 22, 2024. | CI |
Fiscal Period: March | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 2.89 | 3.34 | 4.75 | 2.83 | 2.51 | |||||
Return on Total Capital | 3.79 | 4.31 | 6.23 | 3.66 | 3.19 | |||||
Return On Equity % | 7.47 | 9.96 | 15.92 | 10.66 | 5.76 | |||||
Return on Common Equity | 7.03 | 10.19 | 16.66 | 11.06 | 6.06 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 22.19 | 24.25 | 23.48 | 20.3 | 21.19 | |||||
SG&A Margin | 14.08 | 13.67 | 11.68 | 12.01 | 12.62 | |||||
EBITDA Margin % | 9.04 | 13.02 | 13.45 | 9.73 | 10.35 | |||||
EBITA Margin % | 5.2 | 6.7 | 8.23 | 4.83 | 4.91 | |||||
EBIT Margin % | 5.15 | 6.7 | 8.23 | 4.83 | 4.91 | |||||
Income From Continuing Operations Margin % | 3.46 | 5.3 | 7.35 | 4.8 | 3.07 | |||||
Net Income Margin % | 2.83 | 4.78 | 6.82 | 4.41 | 2.86 | |||||
Net Avail. For Common Margin % | 2.83 | 4.78 | 6.82 | 4.41 | 2.86 | |||||
Normalized Net Income Margin | 2.43 | 3.92 | 5.68 | 3.23 | 3.37 | |||||
Levered Free Cash Flow Margin | 1.56 | 6.39 | -6.29 | -4.34 | -1.84 | |||||
Unlevered Free Cash Flow Margin | 1.81 | 6.64 | -6.13 | -4.14 | -1.55 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.9 | 0.8 | 0.92 | 0.94 | 0.82 | |||||
Fixed Assets Turnover | 2.88 | 2.45 | 3.06 | 3.26 | 2.79 | |||||
Receivables Turnover (Average Receivables) | 4.6 | 4.35 | 4.91 | 5.2 | 4.87 | |||||
Inventory Turnover (Average Inventory) | 3.53 | 3.36 | 3.93 | 3.69 | 3.09 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.63 | 1.69 | 1.46 | 1.57 | 1.74 | |||||
Quick Ratio | 1 | 1.04 | 0.8 | 0.8 | 0.89 | |||||
Operating Cash Flow to Current Liabilities | 0.24 | 0.37 | 0.13 | 0.15 | 0.24 | |||||
Days Sales Outstanding (Average Receivables) | 79.5 | 83.99 | 74.27 | 70.16 | 75.1 | |||||
Days Outstanding Inventory (Average Inventory) | 103.62 | 108.72 | 92.85 | 98.79 | 118.51 | |||||
Average Days Payable Outstanding | 52.05 | 50.96 | 39.99 | 39.39 | 45.38 | |||||
Cash Conversion Cycle (Average Days) | 131.07 | 141.75 | 127.13 | 129.56 | 148.23 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 90.62 | 74.79 | 82.53 | 83.58 | 76.84 | |||||
Total Debt / Total Capital | 47.54 | 42.79 | 45.21 | 45.53 | 43.45 | |||||
LT Debt/Equity | 54.66 | 43.02 | 39.58 | 41.86 | 43.93 | |||||
Long-Term Debt / Total Capital | 28.68 | 24.61 | 21.69 | 22.8 | 24.84 | |||||
Total Liabilities / Total Assets | 58.92 | 56.22 | 58.29 | 57.29 | 55.56 | |||||
EBIT / Interest Expense | 12.53 | 16.86 | 32.52 | 14.93 | 10.92 | |||||
EBITDA / Interest Expense | 22 | 32.79 | 53.14 | 30.08 | 23.03 | |||||
(EBITDA - Capex) / Interest Expense | 8.93 | 17.22 | 26.92 | 8.3 | 4.71 | |||||
Total Debt / EBITDA | 4.55 | 3.23 | 3.07 | 4.04 | 4.18 | |||||
Net Debt / EBITDA | 3.32 | 1.99 | 2.23 | 3.02 | 3.02 | |||||
Total Debt / (EBITDA - Capex) | 11.21 | 6.16 | 6.06 | 14.63 | 20.41 | |||||
Net Debt / (EBITDA - Capex) | 8.17 | 3.79 | 4.41 | 10.94 | 14.74 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -9.71 | -9.5 | 33.09 | 16.55 | -6.91 | |||||
Gross Profit, 1 Yr. Growth % | -6.06 | -1.11 | 28.89 | 0.73 | -2.8 | |||||
EBITDA, 1 Yr. Growth % | -15.32 | 30.33 | 37.55 | -15.75 | -0.91 | |||||
EBITA, 1 Yr. Growth % | -26.05 | 16.61 | 63.65 | -31.66 | -5.33 | |||||
EBIT, 1 Yr. Growth % | -26.22 | 17.7 | 63.65 | -31.66 | -5.33 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -46.5 | 38.73 | 84.6 | -23.97 | -40.34 | |||||
Net Income, 1 Yr. Growth % | -50.15 | 52.52 | 90.05 | -24.6 | -39.71 | |||||
Normalized Net Income, 1 Yr. Growth % | -39.57 | 45.79 | 92.69 | -33.65 | -2.87 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -49.45 | 52.87 | 89.75 | -23.75 | -39.01 | |||||
Accounts Receivable, 1 Yr. Growth % |